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Abstract
Given clear evidence that smoking lowers weight, it is possible that individuals with higher body mass index (BMI) smoke in
order to lose or maintain their weight. We performed Mendelian randomization (MR) analyses of the effects of BMI on
smoking behaviour in UK Biobank and the Tobacco and Genetics Consortium genome-wide association study (GWAS), on
cotinine levels and nicotine metabolite ratio (NMR) in published GWAS and on DNA methylation in the Avon Longitudinal
Study of Parents and Children. Our results indicate that higher BMI causally influences lifetime smoking, smoking initiation,
smoking heaviness and also DNA methylation at the aryl-hydrocarbon receptor repressor (AHRR) locus, but we do not see
evidence for an effect on smoking cessation. While there is no strong evidence that BMI causally influences cotinine levels,
suggestive evidence for a negative causal influence on NMR may explain this. There is a causal effect of BMI on smoking,
but the relationship is likely to be complex due to opposing effects on behaviour and metabolism.
Introduction
Smoking and obesity are amongst the leading preventable
causes of mortality and morbidity worldwide (1). Understanding
pathways that contribute to these risk factors, and the nature
of the relationship between them, is therefore of paramount
importance for disease prevention. Observationally, current
smoking is often associated with lower body mass index (BMI)
(2). However, heavy smoking has been found to be associated
with higher BMI (2,3). Given the clustering of unhealthy
behaviours such as smoking, low physical activity and poor
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diet (4) and the strong links between smoking, obesity and
sociodemographic factors (5), establishing the existence of and
direction of causality is difficult.
Mendelian randomization (MR), which uses genetic variants
associated with exposures as proxies, can help to overcome
problems of confounding and reverse causality because, in the-
ory, genetic variants associated with the exposure of interest
should be inherited independently of other genetic variants
and environmental factors (6). There is good evidence from MR
studies, using a genetic variant that influences the number
of cigarettes consumed per day among smokers, that heav-
ier smoking causes a reduction in BMI and other measures of
adiposity (7–9). This may be explained by nicotine increasing
metabolic rate and/or lowering appetite and therefore changing
energy balance (2). To support this, there is a large body of
evidence showing that smoking cessation is accompanied by
weight gain (10–15), thoughwith large individual variation in the
amount gained.
Given that smoking lowers body weight, it is plausible that
the association between BMI and smoking is bidirectional; that is
more overweight individuals may take up smoking, smoke more
heavily or continue to smoke rather than quit, in order to lower
weight.Weight gain is commonly cited as a concern for smokers
who are considering quitting smoking (10). This has been found
most consistently in women (10), although there is also evidence
that weight concern is associated with motivation to quit smok-
ing in men (16).Weight concern or body dissatisfaction amongst
adolescents may also increase the likelihood of smoking initia-
tion (17,18). However, it is important to note that the relationship
betweenweight concern and BMI is complex; for example, itmay
be U-shaped in males (19). Amongst young people in the Avon
Longitudinal Study of Parents and Children (ALSPAC), higher BMI
was associated with smoking initiation in females, but not in
males, whereas body dissatisfaction was associated with higher
risk of smoking initiation in both sexes (20). Smoking and obesity
are also both associated with increased risk of anxiety and
depression (21), and there is evidence that the link between
higher BMI and depressive symptoms is causal (22). Therefore,
it is possible that BMI could lead to smoking through its effects
onmental health, although strong evidence of causality between
mental health and smoking is yet to be established.
In addition to behavioural links, it is possible that BMI could
alter smoking behaviour via physiological effects. Higher BMI
could result in lower blood nicotine levels for the same amount
smoked, due to higher total blood volume or absorption of nico-
tine or its metabolites by fatty tissue (23). It has been demon-
strated that BMI is negatively correlated with nicotine levels
following administration of nicotine replacement therapy (24).
This could mean that individuals with higher BMI would need
to smoke more in order to experience the same effect of nico-
tine. BMI may also affect nicotine metabolism, which is com-
monly measured by the nicotine metabolite ratio (NMR). Studies
have shown that individuals with higher NMR (reflecting faster
metabolism of nicotine) smoke more heavily and are less likely
to give up smoking (25,26). Observationally, BMI tends to be
negatively correlated with NMR (27). This could plausibly be
because NMR lowers BMI through its effect on increasing smok-
ing, although it has been argued that evidence points towards
the relationship being in the opposite direction, from BMI to
NMR (27).
A previous genetic analysis demonstrated that higher genet-
ically determined BMI was associated with increased likelihood
of smoking initiation and higher tobacco consumption (28). This
was interpreted by the authors as shared genetic aetiology for
BMI and smoking rather than a causal effect of BMI on smoking.
For example, variants in the brain-derived neurotrophic factor
(BDNF) gene associate with both BMI and smoking initiation at
genome-wide significance level (29,30). A more recent MR anal-
ysis provided evidence that BMI causally influences smoking
behaviour, but was restricted to discrete self-report smoking
phenotypes (e.g. initiation, heaviness of smoking) (31).
We sought to extend this work and explore the potential
causal effect of BMI on smoking using a larger number of genetic
variants and MR methods, which are more robust to potential
pleiotropy (32–34). Using genetic variants associated with BMI
from the largest published genome-wide association studies
(GWAS) of BMI to date (30), we investigated whether BMI causes
differences in smoking behaviour and total tobacco exposure by
looking at both self-reportedmeasures of smoking and biological
measures of exposure (cotinine and DNAmethylation). Our self-
report measures included individual smoking phenotypes and
a composite measure of lifetime smoking. We also used this
approach to investigate whether BMI causally influences NMR.
We performed analyses using several data sets: the Tobacco and
Genetics (TAG) Consortium GWAS (29), the Cotinine Consortium
GWAS (35) and the largest NMRGWAS conducted to date (36), the
UK Biobank (37) and ALSPAC (38).
Results
Association of BMI genetic risk score with BMI
Within UK Biobank, each SD increase in genetic risk score was
associated with a 0.64 kg/m2 increase in BMI (95% confidence
interval (CI): 0.62–0.65). There was evidence that the association
of the BMI genetic risk differed by smoking status (P for hetero-
geneity ≤0.001), with the strongest association seen in current
smokers (Supplementary Material, Fig. S3).
MR analysis of effect of BMI on self-reported smoking
behaviours
There was evidence that BMI was causally associated with
increased likelihood of smoking initiation (Fig. 1; Supplementary
Material, Tables S1 and S2). In inverse variance weighted (IVW)
MR analysis combining the TAG andUKBiobank results, a one SD
increase in BMI increased the odds of being an ever rather than a
never smoker by 19% (OR: 1.19, 95% CI: 1.11–1.27). Findings from
weightedmedian,MR Egger andmode weighted regression were
consistent with a positive association with smoking initiation,
although magnitudes of association were lower in median and
weighted mode regression. In MR Egger analysis, there was no
clear evidence for directional pleiotropy.
We also found some evidence for a causal effect of higher BMI
on smoking heaviness within smokers (Fig. 1). In IVW analysis,
each SD increase in BMI increased smoking heaviness by 1.45
(95% CI: 1.03–1.86) additional cigarettes per day. Estimates of
these associations were similar for median and weighted mode
regression. However, the combined estimate from MR Egger was
not consistentwith the findings from IVW (β = 0.04, 95%CI:−0.94
to 1.03).
A one SD increase in BMI was associated with a −0.01 log
unit decrease in age at initiation (95% CI: −0.02 to 0.0003) in
IVW analysis. Results from the other analytical approaches were
consistent with this effect but were imprecise (Fig. 1). There was
no clear evidence using any of the approaches for a causal effect
of BMI on smoking cessation (Fig. 1).
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Figure 1. Association between BMI genetic risk score and smoking phenotypes in TAG and UK Biobank. Age at initiation in log units.
Finally, the analysis of lifetime smoking provided clear evi-
dence in the IVW analysis for a causal effect of BMI on increased
lifetime smoking behaviour (β = 0.12, 95% CI: 0.08–0.16; Supple-
mentary Material, Table S2). Weighted median and MR Egger
estimates supported the direction of effect but the weighted
mode estimate showed no clear evidence of an effect (β = −0.01,
95% CI: −0.07 to 0.06). The MR Egger intercept indicated no clear
evidence of directional pleiotropy.
Results were similar for males and females in UK Biobank
(P-values for heterogeneity in comparisons of IVW analyses all
>0.2; Supplementary Material, Tables S3 and S4).
MR analysis of effect of BMI on DNA methylation
In the ALSPAC mothers, DNA methylation at aryl-hydrocarbon
receptor repressor (AHRR) was negatively associated with being
a smoker and with cigarettes per day (Supplementary Material,
Table S5).
There was evidence for a causal effect of BMI on AHRR DNA
methylation in the ALSPAC mothers in ARIES (Table 1). In IVW
MR analysis, a one SD increase in BMI decreased AHRR DNA
methylation by 0.33 SD (95% CI: −0.55 to −0.11) in samples taken
∼18 years post pregnancy and by 0.23 SD (95% CI: −0.47 to 0.01)
in the antenatal samples. Evidence from the pleiotropy robust
methods were consistent with the results from IVW analysis,
but evidence for associations in the antenatal samples wasweak
using these approaches.
MR analysis of effect of BMI on cotinine levels
Using data from the cotinine GWAS, we found no clear evidence
for a causal effect of BMI on cotinine levels (beta from IVW: 0.05
SD, 95% CI: −0.13 to 0.23; Table 2).
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Table 1. MR of causal effect of BMI on AHRR methylation (cg05575921) in ARIES (N = up to 846)
Follow-up methylation (mean age, 47 years) Antenatal methylation (mean age, 29 years)
Beta (95% CI) P Beta (95% CI) P
Inverse variance weighted −0.33 (−0.55 to −0.11) 0.004 −0.23 (−0.47 to 0.01) 0.06
MR Egger slope
MR Egger intercept
−0.72 (−1.25 to −0.19)
0.01 (−0.003 to 0.025)
0.008
0.11
−0.33 (−0.92 to 0.25)
0.003 (−0.01 to 0.02)
0.26
0.70
Weighted median regression −0.39 (−0.75 to −0.02) 0.04 −0.12 (−0.51 to 0.26) 0.53
Weighted mode regression −0.54 (−1.00 to −0.08) 0.02 −0.19 (−0.68 to 0.31) 0.46
Using 96 SNPs from Locke et al. GWAS. Coefficients represent SD change in methylation per SD change in BMI, adjusted for age, PCs, cell counts and batch.
Table 2. MR of causal effect of BMI on cotinine (N = up to 4548)
Cotinine (SD)
Beta (95% CI) P
Inverse variance weighted 0.05 (−0.13 to 0.23) 0.62
MR Egger slope
MR Egger intercept
0.02 (−0.41 to 0.46)
0.001 (−0.01 to 0.01)
0.91
0.92
Weighted median regression 0.03 (−0.26 to 0.32) 0.84
Weighted mode regression −0.005 (−0.370 to 0.360) 0.98
Using 95 SNPs from Locke et al. GWAS. Coefficients represent SD change in
cotinine per SD change in BMI. I-squared for heterogeneity in IVW analysis: 0%,
P = 0.87.
MR analysis of effect of BMI on NMR
Across the FinnTwin, FINRISK and Young Finns Study (YFS)
studies, there was suggestive evidence that higher BMI was
associated with lower NMR (−0.45 per SD increased in BMI, 95%
CI:−0.78 to−0.12 in IVWanalysis). Themagnitude of association
was consistent across the other approaches; however, there
was a large amount of heterogeneity between the studies for
weighted median and weighted mode analyses. Clear evidence
for a negative association between BMI and NMR was only seen
in the FinnTwin study (Supplementary Material, Table S6).
MR analysis of the effect of smoking heaviness on BMI
Consistent with previous studies (7,8), the minor allele of the
smoking heaviness related variant, rs16969968, increased num-
ber of cigarettes smoked per day by 0.95 (95% CI: 0.79–1.11,
N = 22 568) and decreased BMI in current (beta per minor allele:
−0.21, 95% CI: −0.29 to −0.13, N = 32 685), but not former (beta
per minor allele: 0.01, 95% CI: −0.03 to 0.05, N = 116 158) or
never smokers (beta per minor allele: 0.02, 95% CI: −0.02 to 0.05,
N = 181 333, P for interaction between smoking groups<0.001) in
UK Biobank.
Discussion
Using data from multiple cohorts, we find that higher BMI
increases the likelihood of becoming a smoker and increases
smoking heaviness within current smokers. This finding
is supported by the analysis of lifetime smoking and the
negative association between the BMI genetic risk score and
AHRR methylation (which is hypomethylated among smokers).
However, the BMI genetic risk score was not associated with
cotinine levels and showed some evidence of a negative
association with the NMR, which we might expect to reduce
cigarette consumption (25). In agreement with previous findings
(7), we showed that heavier smoking lowers BMI. Taken together,
these results suggest that there may be bidirectional causal
effects between smoking phenotypes and BMI, and that these
may act in opposing directions. We find no clear evidence for
differences between males and females in these effects.
Our results for smoking initiation and cigarettes per day are
similar to those presented by Thorgeirsson et al. (28), who used
the TAG data set but only 32 BMI-related genetic variants, from
an earlier GWAS. It is possible that, as they suggest, the effects
observed here represent a shared genetic aetiology between
BMI and smoking behaviour. However, our results for smoking
initiation and cigarettes per day were supported by methods
that are more robust to the pleiotropy assumption, MR-Egger
and weighted median and weighted mode MR, giving weight to
the explanation that this finding represents a causal effect of
BMI on smoking uptake and heaviness. This was supported by
the negative association we observed between the BMI genetic
risk score and DNA methylation at AHRR, given that smoking
is associated with lower DNA methylation at AHRR (39). Our
finding could, in part, explain the positive association found
between the BMI genetic risk score and certain types of lung
cancer (40). Although associations via smoking were ruled out in
this analysis, sample sizes for testing associations with smoking
behaviour were small.
We did not find clear evidence for an effect of BMI on
cotinine levels, which might be expected if having higher
BMI increases number of cigarettes smoked per day (and
therefore total tobacco intake). It is possible that whilst BMI
increases total tobacco intake and therefore absolute cotinine
levels, individuals with higher BMI have lower blood cotinine
concentration due to higher total blood volume (meaning that
cotinine is more diluted in the blood) or greater absorption of
cotinine by adipose tissue (23). These opposing effects could lead
to a negligible net effect of BMI on cotinine levels.
We observed some evidence for a causal negative effect
of BMI on the NMR, although findings should be interpreted
with caution as they were very heterogeneous between studies.
Although this does not rule out an effect of NMR on BMI
mediated through higher tobacco intake, our data provide some
support for BMI lowering NMR, the direction hypothesized by
Chenoweth et al. (27). Given that it is unlikely that BMI affects
plasma cotinine and 3′ hydroxycotinine differentially, this could
point to an effect of BMI on the enzymes that metabolize these
compounds or to indirect effects of BMI via other factors, which
may affect NMR (e.g. alcohol consumption, hormone levels) (27).
Our findings in relation to NMR demonstrate the potential com-
plexity of the BMI-smoking relationship, with opposing effects
on behaviour andmetabolism.However, an overall positive effect
of BMI on tobacco consumption implies that individuals with
higher BMI are still at higher risk of increased tobacco consump-
tion (and therefore the harmful effects of tobacco smoke), even
if having higher BMI may reduce levels of metabolites.
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Figure 2. Two sample MR of effect of BMI on NMR in FinnTwin, FINRISK and YFS.
Although we have attempted to explore both behaviour and
metabolism in our analyses, it is not clear what themechanisms
underlying the association between higher BMI and smoking
initiation and cigarette consumption are. If this is due to indi-
viduals with higher BMI having greater concerns about weight
control, we might also expect to observe evidence for a causal
effect with smoking cessation as fear of weight gain is often
provided as a reason for continuing to smoke (10). Importantly,
interventions that incorporate weight gain concerns or that aim
to tackle weight gain at the same time as smoking cessation
may still be effective as weight concerns are not always strongly
correlated with or may have non-linear relationships with BMI
(19). Given that there is evidence that higher BMI is causally
related to lower socioeconomic status, income and educational
attainment (41) and that lower educational attainment causes
increased smoking (42,43) it is possible that any effect of BMI on
smoking could be via these sociodemographic factors.
There are several limitations to this analysis. Firstly, there is
sample overlap between the BMI GWAS and the smoking, coti-
nine, NMR and GWA studies (estimated to be up to 17%), which
may have biased the results of our two sample MR analyses
in the direction of the observational estimates (44). However,
results for smoking behaviour from UK Biobank (which was not
included in the BMI GWAS) were highly consistent with those
from TAG, suggesting that these results were not driven by bias
due to participant overlap. We also repeated the TAG, cotinine
and NMR analyses using beta coefficients and standard errors
for BMI generated in UK Biobank and these were similar (data
not shown). Secondly, we were unable to test associations of
the BMI genetic risk score with BMI in the outcome data sets in
the two-sample MR analysis. We found some evidence that the
association of the BMI genetic risk score with BMI is stronger
in current than in former or never smokers in UK Biobank.
Therefore, effect sizes should be interpreted with some caution.
In conclusion, our findings support of bidirectional causal
effects between BMI and smoking behaviour. Higher BMI leads
to increased likelihood of smoking and greater tobacco con-
sumption, but smoking also serves to reduce BMI. Given that
BMI and smoking are both major risk factors for disease, this
bidirectional causal relationship highlights the need to consider
both of these together in prevention strategies. If having higher
BMI does increase smoking, interventions aimed at reducing BMI
may also help to prevent smoking uptake.
Materials and Methods
We performed MR analyses using summary data from GWAS
and individual level data from the UK Biobank. The sample
sizes available to use for our different phenotypes provided 80%
power at an alpha level of 5% to detect effect sizes equivalent to
OR 1.07 (smoking initiation), OR 1.12 (smoking cessation), 0.06
SD (heaviness of smoking), 0.04 SD (lifetime smoking), 0.3 SD
(cotinine levels), 0.5 SD (NMR) and 0.6 SD (methylation). Sam-
ple size calculations were performed using http://cnsgenomics.
com/shiny/mRnd/ (45).
Study samples
GWAS summary data: BMI. We obtained summary data on
the association of genetic variants with BMI from the most
recent GIANT BMI GWAS (30). We used the 97 independent
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single nucleotide polymorphisms (SNPs) identified as reaching
genome-wide significance with BMI. Associations between
genetic variants and BMI (betas and standard errors) were
obtained from the meta-analysis of the European sex-combined
data sets (N ≤ 322 135) (30). A full list of SNPs used in each
analysis is shown in Supplementary Material, Table S1.
GWAS summary data: smoking-related outcomes. We obtained
estimates (beta coefficients/odds ratios and standard errors) of
the association of BMI-related genetic variantswith smoking ini-
tiation (ever versus never smoking; N ≤ 74 035), age of initiation
(N ≤ 24 114), smoking cessation (former versus current smoking;
N ≤ 41 278) and smoking heaviness amongst ever smokers
(cigarettes smoked per day;N≤ 38 101) from the TAG Consortium
GWAS (29). We looked up associations of BMI-related SNPs with
cotinine in summary data from a published GWAS of cotinine
levels in current daily cigarette smokers (N ≤ 4 548) (35) and
with theNMR in summary data fromaGWAS in cotinine-verified
current smokers (36). Summary statistics for the NMR GWAS
not adjusted for BMI were obtained from the study authors
separately for the Finnish Twin Study (FinnTwin), the YFS and
the National FINRISK study.
GWAS summary data: DNAmethylation. Weperformed genome-
wide association analysis of DNA methylation at the AHRR
methylation site cg05575921 (the strongest smoking-associated
methylation locus identified to date) (39) in the ALSPAC ARIES
resource (46). ALSPAC is a longitudinal birth cohort, which
recruited 14 541 pregnant women with due dates between
1 April 1991 and 31 December 1992. Information on these
women and their children has been collected at clinics and
via questionnaires ever since (38,47). Please note that the
study website contains details of all the data that is available
through a fully searchable data dictionary (http://www.bris.
ac.uk/alspac/researchers/data-access/data-dictionary/). Ethics
approval for the study was obtained from the ALSPAC Ethics
and Law Committee and the Local Research Ethics Committees.
The ARIES resource includes 1018 mother offspring pairs. DNA
methylation in the mothers was assessed from blood samples
taken at two time points: during pregnancy and∼18 years
later. Genome-wide DNA methylation profiling in ARIES was
performed using the Illumina Infinium HumanMethylation450
BeadChip (450K) array (Illumina, Inc. San Diego, CA) (46). Full
details of the GWAS methods are provided in supplementary
material. The sample used in the GWAS (N ≤ 846) included
smokers and non-smokers. Beta coefficients and standard errors
of the association with methylation for each of the BMI-related
SNPs were obtained from the GWAS summary statistics.
UK Biobank. We also used data on individuals from the UK
Biobank,which recruited over 500 000 individuals (aged between
40 and 70 years) in the UK (48). Individuals attended assessment
centres between 2006 and 2010, where they completed a ques-
tionnaire on lifestyle factors and had blood samples and mea-
surements taken. Individuals were classified as ever smokers if
they had smoked more than 100 cigarettes in their lifetime and
current smokers if they indicated that they were still smoking.
Cigarettes smoked per day amongst current smokers and past
regular smokers was reported on a continuous scale. BMI was
calculated as weight/height [(kg)/(m)2]. Lifetime smoking was
calculated from self-reported smoking duration, cessation and
heaviness. A full description of score construction is provided
elsewhere (49). In this analysis, we included unrelated individ-
uals of white British ancestry (N = 335 921; see supplementary
material for details) (50).
Statistical analysis
In two-sample MR analysis, we calculated the ratio of the SNP-
outcome and SNP-exposure associations (the Wald estimator)
for each of the 97 BMI-related SNPs (Supplementary Material,
Table S1), to give an estimate of the effect of BMI on the outcome.
Where BMI-related SNPs were not available in the outcome
GWAS, proxy SNPs (with an R-squared value of >0.9 with the
original SNP) were used if available. The single SNP estimates
were combined in an IVW random effects meta-analysis, as
outlined by Burgess and colleagues (51), using the mrrobust
package in Stata (52). For the analysis of smoking initiation, we
excluded the genetic variant in BDNF, as this locus is likely to be
pleiotropic and is associated with smoking initiation at genome-
wide significance level (29).
Within UK Biobank, we generated a weighted BMI genetic
risk score from dosage scores of the 97 SNPs, using the weights
from the combined ancestries GIANT analysis (30) and tested
the association of the standardized risk score against measured
BMI using linear regression. We generated our own outcome
summary statistics by calculating associations of each SNP with
smoking behaviour phenotypes using logistic or linear regres-
sion, adjusted for 10 principal genetic components, and pro-
duced causal estimates using the same two-sample MR IVW
method as outlined above. We performed primary analyses in
the full sample, but also stratified by sex, given evidence from
previous literature that the relationship betweenweight concern
and smoking might be stronger in females. Results from TAG
and UK Biobank were meta-analysed using inverse variance
weighted fixed effects meta-analysis (except for lifetime smok-
ing,where a comparable phenotype was not available in the TAG
data).
We also performed analyses that aremore robust to potential
pleiotropy, MR Egger (32), weighted median regression (33)
and the mode-based estimator (34). The MR Egger method is
similar to IVW, but allows the intercept of the regression line
to change. The intercept is a test of directional pleiotropy;
if the intercept differs from zero, this indicates that there
is directional pleiotropy. The slope obtained from MR Egger
is an estimate of the causal effect after taking into account
this directional pleiotropy (32). Weighted median regression
generates a consistent estimate of a causal effect even when
up to 50% of SNPs are invalid instruments (33). The mode-based
estimator method assumes that the most commonly occurring
causal effect estimate is a consistent estimate of the true causal
effect (34).
In addition, we attempted to replicate previous analyses
investigating the causal effect of smoking on BMI (7), using the
rs16969968 functional variant in the CHRNA3-A5-B4 gene cluster,
which increases smoking heaviness (cigarettes smoked per day)
amongst smokers (53). We regressed the rs16969968 SNP on BMI
in never, former and current smokers, adjusting for age, sex and
principal components in UK Biobank.
All analyses were conducted in Stata (version 14.1), with
the exception of the analysis of lifetime smoking, which was
conducted in R (R Core Team, 2013). Scatter plot of the genetic
associations with BMI against the genetic associations with
major outcome variables are presented in Supplementary Mate-
rial, Figures S1 and S2.
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